发明公开
EP2863909A1 COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO [4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS
审中-公开
WITH PDE-2抑制剂如1-芳基-4-甲基组合[1,2,4]三唑并[4,3-A]喹喔啉和PDE-10抑制剂用于在神经系统和代谢性疾病的治疗中使用
- 专利标题： COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO [4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS
- 专利标题（中）： WITH PDE-2抑制剂如1-芳基-4-甲基组合[1,2,4]三唑并[4,3-A]喹喔啉和PDE-10抑制剂用于在神经系统和代谢性疾病的治疗中使用
-
申请号： EP13731752.5申请日： 2013-06-25
-
公开(公告)号： EP2863909A1公开(公告)日： 2015-04-29
- 发明人: MEGENS, Antonius, Adrianus, Hendrikus, Petrus , LANGLOIS, Xavier, Jean, Michel , VANHOOF, Greta, Constantia, Peter , ANDRÉS-GIL, José, Ignacio , DE ANGELIS, Meri , BUIJNSTERS, Peter, Jacobus, Johannes, Antonius , TRABANCO-SUÁREZ, Andrés, Avelino , ROMBOUTS, Frederik, Jan, Rita
- 申请人： Janssen Pharmaceutica N.V.
- 申请人地址： Turnhoutseweg 30 2340 Beerse BE
- 专利权人： Janssen Pharmaceutica N.V.
- 当前专利权人： Janssen Pharmaceutica N.V.
- 当前专利权人地址： Turnhoutseweg 30 2340 Beerse BE
- 代理机构： Garcia Prieto, Maria
- 优先权： EP12173681 20120626
- 国际公布： WO2014001314 20140103
- 主分类号： A61K31/4709
- IPC分类号： A61K31/4709 ; A61K31/517 ; A61K31/5377 ; A61P21/00 ; A61K45/06 ; A61K31/4725 ; A61K31/472
摘要：
The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE10). In particular, the invention relates to combinations of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051324 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases.
公开/授权文献
信息查询
IPC分类:
